These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28847988)

  • 21. Latent infection with Kaposi's sarcoma-associated herpesvirus enhances retrotransposition of long interspersed element-1.
    Nakayama R; Ueno Y; Ueda K; Honda T
    Oncogene; 2019 May; 38(22):4340-4351. PubMed ID: 30770900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA.
    Tagawa T; Gao S; Koparde VN; Gonzalez M; Spouge JL; Serquiña AP; Lurain K; Ramaswami R; Uldrick TS; Yarchoan R; Ziegelbauer JM
    Proc Natl Acad Sci U S A; 2018 Dec; 115(50):12805-12810. PubMed ID: 30455306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nm23-H1 induces apoptosis in primary effusion lymphoma cells via inhibition of NF-κB signaling through interaction with oncogenic latent protein vFLIP K13 of Kaposi's sarcoma-associated herpes virus.
    Mohanty S; Kumar A; Das P; Sahu SK; Mukherjee R; Ramachandranpillai R; Nair SS; Choudhuri T
    Cell Oncol (Dordr); 2022 Oct; 45(5):967-989. PubMed ID: 35964258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation.
    Jiang G; Mendes EA; Kaiser P; Wong DP; Tang Y; Cai I; Fenton A; Melcher GP; Hildreth JE; Thompson GR; Wong JK; Dandekar S
    PLoS Pathog; 2015 Jul; 11(7):e1005066. PubMed ID: 26225771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
    Bhatt S; Ashlock BM; Toomey NL; Diaz LA; Mesri EA; Lossos IS; Ramos JC
    J Clin Invest; 2013 Jun; 123(6):2616-28. PubMed ID: 23635777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic analysis of a xenograft mice model for KSHV+ primary effusion lymphoma (PEL).
    Dai L; Trillo-Tinoco J; Bai L; Kang B; Xu Z; Wen X; Del Valle L; Qin Z
    PLoS One; 2014; 9(2):e90349. PubMed ID: 24587336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upregulation of MicroRNA 711 Mediates HIV-1 Vpr Promotion of Kaposi's Sarcoma-Associated Herpesvirus Latency and Induction of Pro-proliferation and Pro-survival Cytokines by Targeting the Notch/NF-κB-Signaling Axis.
    Yan Q; Zhao R; Shen C; Wang F; Li W; Gao SJ; Lu C
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target.
    Hughes DJ; Wood JJ; Jackson BR; Baquero-Pérez B; Whitehouse A
    PLoS Pathog; 2015 Mar; 11(3):e1004771. PubMed ID: 25794275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR/Cas9 ablating viral microRNA promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus.
    Liang Z; Qin Z; Riker AI; Xi Y
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1400-1405. PubMed ID: 33092788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Kaposi's Sarcoma-Associated Herpesvirus ORF21 Tyrosine Kinase and Viral Lytic Reactivation by Tyrosine Kinase Inhibitors Approved for Clinical Use.
    Beauclair G; Naimo E; Dubich T; Rückert J; Koch S; Dhingra A; Wirth D; Schulz TF
    J Virol; 2020 Feb; 94(5):. PubMed ID: 31826996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing new ceramide analogs and identifying novel sphingolipid-controlled genes against a virus-associated lymphoma.
    Chen J; Goyal N; Dai L; Lin Z; Del Valle L; Zabaleta J; Liu J; Post SR; Foroozesh M; Qin Z
    Blood; 2020 Nov; 136(19):2175-2187. PubMed ID: 32518949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions.
    Whitby D; Marshall VA; Bagni RK; Miley WJ; McCloud TG; Hines-Boykin R; Goedert JJ; Conde BA; Nagashima K; Mikovits J; Dittmer DP; Newman DJ
    Int J Cancer; 2007 Jan; 120(2):321-8. PubMed ID: 17066452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 Vpr Inhibits Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Inducing MicroRNA miR-942-5p and Activating NF-κB Signaling.
    Yan Q; Shen C; Qin J; Li W; Hu M; Lu H; Qin D; Zhu J; Gao SJ; Lu C
    J Virol; 2016 Oct; 90(19):8739-53. PubMed ID: 27440900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting FoxO proteins induces lytic reactivation of KSHV for treating herpesviral primary effusion lymphoma.
    Lan J; Wang Y; Yue S; Xu D; Li Y; Peng X; Hu J; Ju E; He S; Li T
    PLoS Pathog; 2023 Aug; 19(8):e1011581. PubMed ID: 37594999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diallyl trisulfide induces apoptosis by suppressing NF-κB signaling through destabilization of TRAF6 in primary effusion lymphoma.
    Shigemi Z; Furukawa Y; Hosokawa K; Minami S; Matsuhiro J; Nakata S; Watanabe T; Kagawa H; Nakagawa K; Takeda H; Fujimuro M
    Int J Oncol; 2016 Jan; 48(1):293-304. PubMed ID: 26647777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxidant species are involved in T/B-mediated ERK1/2 phosphorylation that activates p53-p21 axis to promote KSHV lytic cycle in PEL cells.
    Gonnella R; Yadav S; Gilardini Montani MS; Granato M; Santarelli R; Garufi A; D'Orazi G; Faggioni A; Cirone M
    Free Radic Biol Med; 2017 Nov; 112():327-335. PubMed ID: 28801242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency.
    Mariggiò G; Koch S; Zhang G; Weidner-Glunde M; Rückert J; Kati S; Santag S; Schulz TF
    PLoS Pathog; 2017 Apr; 13(4):e1006335. PubMed ID: 28430817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The RNA quality control pathway nonsense-mediated mRNA decay targets cellular and viral RNAs to restrict KSHV.
    Zhao Y; Ye X; Shehata M; Dunker W; Xie Z; Karijolich J
    Nat Commun; 2020 Jul; 11(1):3345. PubMed ID: 32620802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation.
    Chen J; Dai L; Goldstein A; Zhang H; Tang W; Forrest JC; Post SR; Chen X; Qin Z
    PLoS Pathog; 2019 Dec; 15(12):e1008156. PubMed ID: 31790497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycolysis, Glutaminolysis, and Fatty Acid Synthesis Are Required for Distinct Stages of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication.
    Sanchez EL; Pulliam TH; Dimaio TA; Thalhofer AB; Delgado T; Lagunoff M
    J Virol; 2017 May; 91(10):. PubMed ID: 28275189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.